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Abstract: Combined individually tailored methods for diagnosis and therapy (theragnostics) 
could be beneficial in destructive diseases, such as rheumatoid arthritis. Nanoparticles are 
promising candidates for theragnostics due to their excellent biocompatibility. Nanoparticle 
modifications, such as improved surface coating, are in development to meet various require-
ments, although safety concerns mean that modified nanoparticles require further review before 
their use in medical applications is permitted. We have previously demonstrated that iron 
oxide nanoparticles with amino-polyvinyl alcohol (a-PVA) adsorbed on their surfaces have the 
unwanted effect of increasing human immune cell cytokine secretion. We hypothesized that this 
immune response was caused by free-floating PVA. The aim of the present study was to prevent 
unwanted immune reactions by further surface modification of the a-PVA nanoparticles. After 
cross-linking of PVA to nanoparticles to produce PVA-grafted nanoparticles, and reduction of 
their zeta potential, the effects on cell viability and cytokine secretion were analyzed. PVA-
grafted nanoparticles still stimulated elevated cytokine secretion from human immune cells; 
however, this was inhibited after reduction of the zeta potential. In conclusion, covalent cross-
linking of PVA to nanoparticles and adjustment of the surface charge rendered them nontoxic 
to immune cells, nonimmunogenic, and potentially suitable for use as theragnostic agents.
Keywords: iron oxide nanoparticles, cytokine secretion, cell viability, polyvinyl alcohol, 
cross-linking, surface charge
Introduction
The rising costs of human health care clearly reflect an urgent demand for improved 
medical care. Treatment strategies include both early detection of disease, ideally before 
damage can occur, and targeting of therapeutic measures, thereby diminishing unwanted 
adverse effects. A combination of both individually tailored diagnosis and therapy, the 
so called “theragnostic approach”, would be desirable. Nanoparticles (NP) are very 
promising tools in this field, and are already used in various medical applications.1–5 
Organic NP include liposomes, dendrimer constructs, ALB-bound formulations, and 
polymeric NP, in which the specific, potentially therapeutic molecules are enclosed. 
These organic NP are mainly used for drug delivery, because they display improved 
pharmacokinetics and pharmacodynamics compared to the drugs themselves. Further-
more, the organic NP delivery system is biocompatible and biodegradable.6 This is not 
the case for inorganic NP, such as metallic NP, quantum dots, or carbon nanotubes, 
which are mainly used for diagnostic purposes – for example, as contrast enhancers for 
magnetic resonance imaging (MRI).7–11 The therapeutic application of inorganic NP is 
constantly developing, although to a lesser extent than that of organic NP.6 Examples 
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of therapeutic applications are drug delivery systems,12,13 stem 
cell tracking,14,15 and thermotherapy.3,16
Superparamagnetic iron oxide nanoparticles (SPION) are 
promising inorganic NP. They have been intensively inves-
tigated over the last 20 years for various in vitro and in vivo 
biomedical applications.1 One advantage they offer is that they 
have excellent physicochemical properties, leading to improved 
efficacy and specificity; for example, as contrast enhancers in 
in vivo imaging techniques. They exhibit high magnetization 
in the presence of an external magnetic field, whereas this mag-
netization is lost when the external magnetic field is removed.17 
MRI is an important noninvasive tool to visualize organs, tis-
sues, and pathological changes or treatment outcomes.18,19 In the 
field of chronic, systemic inflammatory autoimmune diseases, 
such as rheumatoid arthritis, there is a need for close and regular 
monitoring of disease activity. Achieving this goal is important, 
since damage to cartilage and bone as a consequence of this 
destructive disease is irreversible;20 hence, early diagnosis is 
needed. This may be facilitated by use of specially developed 
SPION as effective, specific, and safe theragnostic agents. 
The surface of NP can be coated with biocompatible 
substances to ensure that their application is safe. One 
example is the siloxane-coated SPION, ferumoxsil (trade 
name Lumirem® or GastroMARK®), which is already used 
as a contrast agent in gastroenterology, to distinguish the 
bowel from other abdominal structures.21 
Furthermore, SPION are endocytosed by cells, particu-
larly immune cells such as monocytes and macrophages, 
which are dedicated phagocytes that migrate into inflamed 
tissues.22–25 SPION can be further functionalized by surface 
coating using proteins, peptides, antibodies, polymers, car-
bohydrates, aptamers, DNA, RNA, or oligosaccharides.17 
The composition and characteristics of the SPION surface 
have a strong influence on their stability, distribution, and 
biocompatibility, with regard to cellular uptake and cyto-
toxicity. Although commercially available SPION have 
been approved for human use, they present some risks when 
used for treatment purposes, and these are currently being 
reevaluated.4,26–29 Currently, there are no accepted standard-
ized protocols or toxicity assays available that could help to 
compare the properties of the many SPION which are under 
development. Moreover, there is also a lack of standardized 
preclinical and clinical study protocols for this purpose. 
Nevertheless, in vitro assays demonstrate that polyvinyl 
alcohol (PVA) coated SPION can alter the metabolism of 
immune cells. Previously, we showed that amino (a)-PVA-
SPION do not affect the survival25 or activity30 of human 
immune cells; however, these particles do cause unwanted 
immune reactions, in terms of increased cytokine secretion.25 
To enable safe medical application of these NP, modification 
of a-PVA-SPION is necessary. Because the coating of these 
NP was not optimally controlled in former experiments, it 
was not clear if the effects observed were due to the coated 
SPION themselves or to free-floating PVA polymer, which 
could trigger an immune reaction. 
In this study, we demonstrate that it is advantageous to 
precisely modify the SPION surface and show how this posi-
tively influences the responses of human immune cells.
Materials and methods
Materials
All chemicals were of analytical reagent grade and used with-
out further purification. Three types of PVA were used during 
this study. PVA Mowiol 4–88 (PVA
4–88
) was provided by 
Merck®KGaA (Darmstadt, Germany). PVA
4–88
 is a classical 
PVA without any functional group, has a molecular weight of 
30,000, and a degree of hydrolysis of 88%. Amino-functionalized 
PVA M12 (PVA
M12
), also used in a previous study,22 was sup-
plied by Erkol® (Tarragona, Spain). PVA
M12
 contains 4% amino 
(NH
2
) groups and has a molecular weight of between 80,000 and 
120,000. PVA KL506 (PVA
KL506
) was supplied by Kuraray® 
(Kuraray Europe GmbH, Hattersheim am Main, Germany). 
PVA
KL506
 has a random distribution of carboxyl groups (COOH) 
and a molecular weight of between 30,000 and 50,000.
SPION synthesis and characterization
Preparation of naked sPION and PVa-coated sPION 
Naked SPION were synthesized according to a published pro-
tocol.15 a-PVAcoated SPION (a-PVA-SPION), were prepared 





at a mass ratio of 45/1 respectively.22 The PVA
4–88
 solution was 
prepared by dissolving this polymer in water at 10% mass/
volume. All solutions were heated for 30 minutes at 90°C to 
improve polymer solubility. The polymer solution was then 
passed through a sterile filter (pore size, 200 nm). Ultrapure 
deionized water (DI water from Seralpur delta; Seral GmbH, 
Ransbach-Baumbach, Germany) was used throughout the 
synthesis. To obtain PVA-grafted SPION, a preliminary step 
of PVA coating was performed with a chemical mass ratio of 
PVA to iron (PVA/Fe) of 7 (PVA
4–88
-SPION-R7) by mixing 
10 volumes of naked SPION with 7 volumes of PVA
4–88
 solution 
and 3 volumes of DI water. The preliminary PVA
4–88
-SPION-R7 
were stored for 1 week at 4°C before synthesis was continued.
Grafting (covalent linking) of PVA onto SPION using 
a silica cross-linking agent: a-PVA-grafted-SPION 
PVA was grafted onto the surface of SPION using a silica 

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Engineering of SPION to reduce immunogenicity
PVA
4–88
-SPION-R7. As described previously,31 this method 
allows reproducible synthesis of PVA-grafted SPION by 
cross-linking the polymer onto the surface of SPION with 
silica. Furthermore, APTES provides amino groups on the 
surface of PVA
4–88
-SPION-R7 to have identical surface 
as previously used a-PVA-SPION functionalized with 
PVA
M12
.22 For one batch of synthesis, 25 mL of PVA
4–88
-
SPION-R7 was diluted in 900 mL of DI water. The pH was 
adjusted to pH 10 with ammonia (25%) and the suspension 
heated to 60°C. Then, 10 mL of APTES was added and the 
reaction continued for 5 hours. The suspension was neutral-
ized to pH 7–8 using HCl (6 M) before loading 25 mL into 
a magnetic separator filled with thin stainless steel wires 
(Frantz® Canister Separator, Model L-1CN; S. G. Frantz 
Company Inc., Tullytown, PA, USA), using a peristaltic 
pump set at 14 mL/min and a magnetic field set at 1 tesla 
(120 V, 1.8 A) (Figure S1). After loading (approximately 
1 hour), the reactor was rinsed with an equivalent of 10 
reactor volumes (10×25 mL) of DI water at 14 mL/min for 
20 minutes. The magnetic field was then removed and the 
suspension released from the separator. The suspension 
obtained was concentrated magnetically to obtain a-PVA-
grafted-SPION at 5 mg of Fe per mL.
For some experiments, the charge of a-PVA-grafted-
SPION was adjusted using a very small amount of PVA
KL506
 
in a mass ratio of PVA
KL506
/Fe of 0.05. The two different 
types of NP generated were a-PVA-grafted-SPION (+) (with 
decreased charge) and a-PVA-grafted-SPION (++) (without 
decreased charge).
Characterization of NP
The mean diameter of the magnetic cores (d
core
, nm) was 
determined by counting 400 diameters/fields using a 
transmission electron microscope (CM12; Philips Elec-
tron Optics, Zürich, Switzerland) at 45,000× magnifica-
tion. Hydrodynamic diameter (d
H
, nm) and zeta potential 
(Z potential, mV) were measured at pH 7, at an ionic 
strength of 10 mM NaCl, by dynamic light scattering, using 
a Malvern NanoZS (Nanosizer 7.2 software; Malvern Instru-
ments, Malvern, UK) and a theoretical refractive index of 
magnetite of 2.42.32 The saturation magnetization (emu/g) 
was obtained from lyophilized SPION before PVA coating, 
using a superconducting quantum interference device.33 The 
chemical composition of SPION, (ie, the concentration of 
iron in mg of Fe per mL), was determined using magnetic 
susceptibility methods.34 In addition, the amount of PVA 
(PVA/Fe in mgPVA/mgFe) present on the surface of SPION 
was calculated by thermogravimetric analyses (TGA; 
Mettler Toledo TGA/SDTA 851e [Columbus, Ohio, USA]) 
of the loss of mass that occurred upon heating from 150°C 
to 800°C (10°C/min) under air (30 mL/min). This provided 
the PVA/Fe.
Antibodies and reagents
Privigen® human immunoglobulin from CSL Behring 
(King of Prussia, PA, USA) was used for flow cytometry. 
Anti-human-CD14-APC-Cy7 and anti-human-CD19-PE-
Cy7 were from BioLegend (San Diego, CA, USA), anti-
human-CD3-Pacific-blue and Annexin V/7AAD apoptosis 
kits were from BD Biosciences (San Jose, CA, USA), and 
anti-human-CD15-APC was from Miltenyi Biotech GmbH 
(Bergisch Gladbach, Germany). Lectin from Phaseolus 
vulgaris (PHA-L) and lipopolysaccharide (LPS) from Sigma-
Aldrich Co. (St Louis, MO, USA) were used for immune cell 
stimulation. The commercially available MRI contrast agent 
ferumoxsil (Lumirem®; Guerbet, Villepinte, France) was 
used as a negative control for the final comparative analysis 
of different NP preparations. 
Whole blood cell viability analysis: sample 
preparation and stimulation 
Venous blood obtained from healthy donors was collected in 
heparinized tubes. Healthy donors provided written informed 
consent before enrollment in the study. The study protocol 
was approved by the responsible local administrative body 
and ethics committee of Charité University Medicine Berlin 
in accordance with the Declaration of Helsinki. 
For each condition, 100 µL of fresh whole blood sam-
ples were diluted with 100 µL of Roswell Park Memorial 
Institute (RPMI) 1640 culture medium (GIBCO; Thermo 
Fisher Scientific, Waltham, MA, USA) supplemented with 
100 U/mL penicillin G, 100 µg/mL streptomycin (both from 
PAA Laboratories GmbH, Pasching, Austria), and 50 µM 
β-mercaptoethanol (Sigma-Aldrich Co.) in MegaBlock® 
96-well 1.2 mL deep-well plates (Sarstedt AG & Co., Nuem-
brecht, Germany). 
Cells were stimulated with LPS (1 µg/mL), PHA-L 
(5 µg/mL), a-PVA-SPION (1, 10 and, 100 µg/mL), or 
a-PVA (1, 10 and, 100 µg/mL), or were untreated, and were 





). Afterwards, supernatants were collected, 
immediately frozen, and stored at -80°C for cytokine secre-
tion analysis, and cells were prepared for flow cytometry 
(see below).
Quantification of secreted cytokines
Secreted cytokines were quantified using a Bio-Plex® Pro 

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





200 system with high-throughput fluidics (all from Bio-Rad 
Laboratories Inc., Hercules, CA, USA). 
Analysis of cell survival by flow 
cytometry
Erythrocytes were lysed by adding 900 µL of erythrocyte 
lysis buffer (0.01 M KHCO
3
, pH 7.5; 0.155 M NH
4
Cl; 
0.1 mM ethylenediaminetetraacetic acid) to 200 µL whole 
blood samples. After incubation for 10 minutes at room tem-
perature, white blood cells were collected by centrifugation 
and the procedure was repeated once. Cell pellets were then 
washed with phosphate-buffered saline (PBS) and nonspecific 
binding was blocked by preincubation with human immuno-
globulin (5 mg/mL) for 10 minutes at 4°C.25 After washing 
the cells with PBS, an antibody-mix (anti-CD3, anti-CD14, 
anti-CD19, and anti-CD15; all antibodies diluted 1/50 in 
PBS) was added, mixed, and the samples were incubated for 
15 minutes at 4°C in the dark. Cells were washed twice and 
Annexin V-PE/7-AAD staining was performed according to 
the manufacturer’s instructions. Cells were analyzed within 
1 hour by flow cytometry using a MACSQuant® analyzer 
equipped with a MACS® MiniSampler (Miltenyi Biotech 
GmbH). The acquired data were analyzed using FlowJo 7.6.1 
software (Tree Star Inc, Ashland, OR, USA). 
statistical analyses
Flow cytometry data were analyzed using GraphPad Prism 
Software (GraphPad Software, Inc., La Jolla, CA, USA) 
and are presented as box and whisker plots (whiskers from 
minimum to maximum), or mean with standard deviation, of 
at least eight independent experiments. Multiple comparisons 
were analyzed by one- or two-way analysis of variance as 
indicated, with Bonferroni’s multiple comparison post hoc 
tests for normally distributed data. Probability values of 
P,0.05 were considered to be statistically significant. 
Results
SPION synthesis and characterization
The method used to obtain a-PVA-grafted-SPION allowed 
the production of 50 mL of NP (at 5 mg of Fe per mL) per 
day in a reproducible manner, with a yield of approximately 
80%. The three types of NP used in this study [PVA-SPION, 
a-PVA-grafted-SPION (++), and a-PVA-grafted-SPION (+)] 
had comparable hydrodynamic diameters and Z potentials. 
The average hydrodynamic diameter of a-PVA-SPION, 
a-PVA-grafted-SPION (++), and a-PVA-grafted-SPION (+) 
were 31±10, 28±8, and 32±7 nm, respectively. The three 
functionalized SPION have higher hydrodynamic diameter 
than naked SPION (14±2 nm) because of the addition of 
polymers, which increase their hydrodynamic diameters. 
The hydrodynamic diameters of the synthesized SPION are 
approximately ten times smaller than that of ferumoxsil, which 
is approximately 300 nm.35 The PVA coating and grafting also 
improved the stability of the naked SPION in either biologi-
cal buffer or cell medium (RPMI from GIBCO in this study) 
for at least 2 months (observed via dynamic light scattering 
measurements over time). The PVA surface functionalization 
did neither affect core sizes (all d
cores
 were 7.2±2.5 nm), nor the 
saturation magnetization (54 emu/g). The d
cores
 and saturation 
magnetization of the synthesized SPION have very similar 
values to those of ferumoxsil, which are 8.4±2.5 nm and 
49.4±0.1 emu/g, respectively.35 The APTES used for the graft-
ing procedure closely resembles the chemistry used to stabilize 
ferumoxsil, which also uses silica (siloxane coating).36 The 
PVA coating could not be observed by transmission electron 
microscope, due to the low contrast of the polymer (Figure S2); 
however, the lack of influence of PVA on the size and mor-
phology of the magnetic cores was evident.
The Z potentials of the three functionalized PVA-SPION 
were all positive at pH 7, at +22±6, +31±5, and +21±2 mV 
for a-PVA-SPION, a-PVA-grafted-SPION (++), and a-PVA-
grafted-SPION (+), respectively. In all three cases, the chemi-
cal groups providing a positive charge at the surface were 




), resulting from 
either PVA
M12
 used in the coating process for a-PVA-SPION 
or APTES for a-PVA-grafted-SPION.
The main difference between the a-PVA-SPION with 
adsorbed polymer and the a-PVA-grafted-SPION (Table 1) 
was a considerable reduction in the amount of PVA used in 
the protocol to produce grafted NP. Chemical analyses and 
Table 1 Physicochemical characterization of SPION with adsorbed amino-PVA (a-PVA-SPION) and grafted PVA with amino groups 
(a-PVA-grafted-SPION)
Nanoparticles dcore (nm) dH (nm) Z potential (mV) Sat mag (emu/g) Conc (mgFe/mL) PVA/Fe mgPVA/mgFe
Naked sPION 7.2±2.5 14±2 1±3 54 10 0
a-PVa-sPION 7.2±2.5 31±10 22±6 54 5 9
a-PVA-grafted-SPION (++) 7.2±2.5 28±8 31±5 54 5 1
a-PVA-grafted-SPION (+) 7.2±2.5 32±7 21±2 54 5 1
Abbreviations: dcore, mean diameter of the magnetic core; dh, hydrodynamic diameter of a-PVA-SPION; Z potential, zeta potential; sat mag, saturation magnetization; conc, 
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Engineering of SPION to reduce immunogenicity
the PVA/Fe mass ratios clearly demonstrated that the quantity 
of PVA used to generate the a-PVA-grafted-SPION with the 
grafting method is much lower (PVA/Fe mass ratio of 1) than 
that used to produce a-PVA-SPION by the adsorption method 
(PVA/Fe mass ratio of 9). These analyses show that, compared 
with passive surface adsorption, covalent grafting of PVA 
requires up to 90% less polymer to stabilize the SPION. 
A PVA/Fe ratio of 1 is in accordance with our previ-
ous work which showed that the minimal ratio needed to 
stabilize SPION is between 1 and 2.31,37 Furthermore, it also 
demonstrates that the PVA adsorbed on a-PVA-SPION 
is free-floating and would be detached from the surface 
when diluted for biological experimentation. A summary 
of the proposed mechanism of surface functionalization 
of SPION with PVA is shown in Figure 1. Finally, no dif-
ference was observed between the amounts of PVA on (+) 
and (++) a-PVA-grafted-SPION, demonstrating that only a 
small amount of PVA is required to change the Z potential 
of these particles. 
Importantly, the grafting method described here enables 
the creation of a stable a-PVA-SPION without any free-
floating polymer, but with physicochemical properties com-
parable to adsorbed-PVA-coated SPION.
effects of free PVa on Il1β secretion in 
human immune cells
Previously, we found that a-PVA-SPION significantly increased 
IL1β secretion, in a dose-dependent manner;25 therefore, 
we investigated whether this effect could result from free 
a-PVA present in the a-PVA-SPION preparation. Whole 
blood samples obtained from eight healthy donors were 
incubated with varying concentrations of a-PVA, and IL1β 
secretion was analyzed in supernatants. Unstimulated cells 
secreted IL1β at a median concentration of 15.5 pg/mL, 
whereas incubation with LPS increased the IL1β secretion 
to 529.1 pg/mL. Incubation with a-PVA alone for 20 hours 
led to an increase relative to unstimulated secretion levels 
in whole blood samples, with median values of IL1β of 
62.45, 371.2, and 653.5 pg/mL at 1, 10, and 100 µg/mL, 
respectively (Figure 2A). Thus, the effect of a-PVA-SPION 
on IL1β secretion25 may be triggered by free a-PVA.
Effects of modified a-PVA-grafted-SPION 
on human immune cells
Next, the effects of a-PVA-grafted-SPION (++) on immune 
cell survival and cytokine secretion were analyzed. As 
already reported for a-PVA-SPION,25 we found no signifi-
cant influence of a-PVA-grafted-SPION (++) on apoptosis 
or viability of human immune cells at concentrations up to 
100 µg/mL (data not shown). Secreted cytokines were ana-
lyzed in the supernatants collected from these whole blood 
viability experiments (n=9) using the Bio-Plex® Suspension 
array system. We found significantly increased secretion of 
the following cytokines in the presence of a-PVA-grafted-
SPION (++) (at 100 µg/mL) compared with the untreated 
control: IL6, IL8, IL10, IL12, IL17, MCP-1, MIP1a, 
MIP1b, FGF-basic, VEGF, and GM-CSF (Figure 2B). 
These effects differed from those observed with a-PVA-
SPION;25 however, cytokine secretion did increase. Prior 
quantitative analyses have demonstrated that the size and 
shape of the charge of NP are the key factors influencing 
NP–cell interactions, especially their intracellular accumula-
tion.38 The SPION used in the present study do not differ in 
their type of surface coating; however, the process of PVA 
cross-linking to the SPION led to the a-PVA-grafted-SPION 
carrying a slightly higher positive charge, in comparison 
with a-PVA-SPION. Therefore, we reduced the Z potential 
of a-PVA-grafted-SPION (++) further, to produce a-PVA-
grafted-SPION (+) and analyzed the effects of this prepara-
tion on human immune cells.
We then compared the effects of the three NP prepara-
tions [a-PVA-SPION, a-PVA-grafted-SPION (++), and 
a-PVA-grafted-SPION (+)] and ferumoxsil, which was 
used at concentrations of 1 and 10 µg/mL because higher 
concentrations were not feasible due to the low concentra-
tion of the commercially available suspension. Ferumoxsil 
is a suspension of siloxane-coated superparamagnetic iron 
Figure 1 Schematic representation of the different methods used to functionalize 
naked SPION (brown circles) with PVA (black lines). 
Notes: The silica precursor (APTES) grafts the PVA onto naked SPION and provides 
amino groups and positive charges to obtain a-PVA-grafted-SPION comparable in 
size, chemistry, and charge to a-PVA-SPION (with adsorbed PVA).
Abbreviations: SPION, superparamagnetic iron oxide nanoparticles; a-PVA, amino- 
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oxide crystals, and is in current routine use as a diagnostic 
contrast agent for MRI examinations of the stomach 
and bowels.
To analyze the influence of the different NP prepara-
tions on human immune cells, we quantified the number of 
Annexin V positive (apoptotic) or 7AAD positive (dead) 
cells, in addition to cell-specific extracellular markers (CD-
antigens) in whole blood samples obtained from ten healthy 
donors incubated with NP. We did not find any significant 


































































































































































Figure 2 Influence of free-floating PVA and a-PVA-grafted-SPION (++) on whole blood cytokine secretion in human immune cells. 
Notes: (A) Free-floating PVA. IL1β secretion was analyzed in supernatants collected from human whole blood samples obtained from healthy donors (n=8) after 20 hours 
incubation with PVA. (B) a-PVA-grafted-SPION (++). Supernatants were collected from whole blood assays [blood samples obtained from healthy donors (n=9)] and analyzed 
for secreted cytokines. Data are presented as box and whisker plots; whiskers represent minimum to maximum. One-way ANOVA: ***P,0.001; **P,0.01; *P,0.05. 
Abbreviations: SPION, superparamagnetic iron oxide nanoparticles; a-PVA, amino-polyvinyl alcohol; ANOVA, analysis of variance; ctrl, control; LPS, lipopolysaccharide; 
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Engineering of SPION to reduce immunogenicity
and viability in the cell types analyzed (Figure 3A). Fur-
thermore, the numbers of apoptotic or dead cells were 
very similar to those identified in cells incubated with 
ferumoxsil.
Analysis of the induction of cytokine secretion triggered 
by incubation with different concentrations of NP clearly 
demonstrated that the effects of a-PVA-grafted-SPION (+) 
are lower compared with those of the other formulations. 
There was a significantly increased secretion of the following 
cytokines after incubation of cells with NP at 100 µg/mL, 
compared with the untreated control (Table S1; Figure 3B): 
a-PVA-SPION led to an increase in IL1β, IL4, IL6, IL8, 
G-CSF, IL17, MCP-1, MIP1a, MIP1b, PDGF, and TNFα; 
and a-PVA-grafted-SPION (++) led to an increase in IL6, 
IL8, IL17, G-CSF, MCP-1, MIP1a, MIP1b, and TNFα; 
whereas a-PVA-grafted-SPION (+) only stimulated the 
production of MCP-1 and MIP1b. All other cytokines were 
unaffected. Ferumoxsil treatment did not cause elevation of 
the concentration of any cytokine (Figure 3B; all median 
concentrations are listed in Table S1).
A representative example, demonstrating the results 
of analysis of IL17 secretion from whole blood samples, 
is shown in Figure 3C. Unstimulated cells secrete IL17 at 
a median concentration of 11 pg/mL, whereas incubation 
with LPS or PHA-L increased IL17 secretion to 72 and 
76.6 pg/mL, respectively. Incubation with a-PVA-SPION 
at 1, 10, and 100 µg/mL led to median values of IL17 of 11, 
49.9, and 66.1 pg/mL secreted from whole blood samples, 
respectively. Incubation with a-PVA-grafted-SPION (++) 
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Figure 3 Influence of different preparations of NP on the viability and cytokine secretion of human immune cells. 
Notes: (A) Whole blood cell survival analysis was performed with blood samples obtained from healthy donors (n=10). Cells were analyzed with Annexin V (an apoptosis 
marker) and 7AAD (a necrosis marker). (B) Supernatants were collected from whole cell blood survival assays and analyzed for secreted cytokines. Red arrow, cytokines 
that were significantly increased compared to untreated controls at a SPION concentration of 100 µg/mL; green arrow, cytokines that remained unchanged. One example, 
IL17 secretion, is presented in detail in (C). Data are presented as box and whisker plots; whiskers represent minimum to maximum. One-way ANOVA: ***P,0.001.
Abbreviations: NP, nanoparticles; SPION, superparamagnetic iron oxide nanoparticles; ANOVA, analysis of variance; a-PVA, amino-polyvinyl alcohol; ctrl, control; 
LPS, lipopolysaccharide; PVA, polyvinyl alcohol.
a-PVA-SPION, with median values of 11, 21.7, and 54.1 
pg/mL at 1, 10, and 100 µg/mL, respectively. Interestingly, 
incubation with a-PVA-grafted-SPION (+) did not lead to an 
increase in the secretion of IL17, even at 100 µg/mL. Finally, 
ferumoxsil had no effect on IL17 secretion (median values 
11 pg/mL for both concentrations). 
Discussion
In a previous study, we demonstrated that a-PVA-SPION 
had no observable toxic effects on the survival of human 
immune cells; however, our analysis of cytokine secretion 
revealed that these particles trigger a dose-dependent release 
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an acute inflammatory process.25 It is difficult to compare 
results from different studies due to varying experimental 
conditions (ie, type of NP, NP concentration or incuba-
tion time, and cell types used); however the results of our 
previous study required further investigation. Therefore, 
the main goal of the present investigation was to identify 
the factors underlying our previous findings of increased 
cytokine production from blood cells after incubation with 
a-PVA-SPION, in order to generate a more suitable and safe 
theragnostic agent. 
Our earlier study suggested that PVA is released from 
a-PVA-SPION; therefore, we hypothesized that free PVA 
may account, at least in part, for the observed effects of these 
NP on human immune cells. From in vivo studies, it is known 
that parenteral PVA administration can induce adverse 
effects. Experiments in rats demonstrated that PVA alone, 
administered intravenously at a dose of 460 mg/kg body 
weight, induced adverse hematological effects (increased 
neutrophils and decreased platelets), clinical chemistry 
indicative of liver effects (increased ALT and AST), and 
histopathology of the liver (hepatocellular necrosis). Such 
effects were either absent or less pronounced when the same 
dose of PVA was adsorbed on SPION.39 
Our initial studies demonstrated that PVA does indeed 
induce a dose-dependent increase in IL1β secretion in human 
immune cells. Similar findings were recently reported in 
mice,40 where systemic administration of high-dose PVA 
provoked an inflammatory response. Gene expression of 
several pro-inflammatory proteins in the murine synovium 
and liver, as well as the serum cytokine concentrations of IL6 
and keratinocyte chemoattractant, were increased.40
The aim of this study was to adapt the SPION, such that 
the release of PVA from the a-PVA-SPION complex was 
prevented. Therefore, we modified the PVA SPION coating to 
obtain covalently bonded a-PVA-SPION with the same physi-
cochemical properties (size, charge, and surface chemistry) as 
the previously analyzed classical a-PVA-SPION.25 This was 
achieved by cross-linking with an amino-silica precursor, which 
also created a positive charge and amino chemical groups. The 
synthesis technique showed good reproducibility, high yield, 
and produced sufficient quantities per batch for experiments 
to study the biological effects of the formulation. 
These newly engineered NP with PVA covalently bonded 
onto the SPION surface (a-PVA-grafted-SPION) were first 
analyzed to determine their effects on human cytokine secre-
tion. In contrast to our expectations, cytokine secretion was 
still increased using this alternative NP preparation; however, 
the cytokines affected differed from those induced after 
incubation with a-PVA-SPION.25 
The surface engineering of NP, which is crucial for their 
functionalization, plays an important role in their stability, 
biocompatibility, and half-life in blood.26,41 Nevertheless, 
our results clearly demonstrate that other factors must also 
influence the effects of SPION on human immune cells, since 
the type of surface coating is similar in both formulations; 
although the PVA is not released from the complex in the 
a-PVA-grafted-SPION, cytokine secretion is still increased, 
albeit differently. 
As the size and shape and the charge of NP are important 
in their interactions with cells,38 and the PVA cross-linking 
process led to a slight increase in the charge of a-PVA-
grafted-SPION compared with a-PVA-SPION, we reduced 
the Z potential of a-PVA-grafted-SPION (++) further, and 
these adapted NP [a-PVA-grafted-SPION (+)] were ana-
lyzed for their interaction with human immune cells. This 
stepwise adaptation of the SPION to reduce the Z potential 
was successful, in that the resultant SPION had no negative 
influence on human immune cell survival and, compared with 
the increased cytokine secretion originally observed for the 
a-PVA-SPION, changes were reduced to a minimum. Only 
the chemokines MCP1 and MIP1b demonstrated increased 
secretion after exposure to a-PVA-grafted-SPION (+), with 
no increase in the levels of pro-inflammatory cytokines (eg, 
IL6, IL17). Whether the secretion of chemokines is advanta-
geous, for example with regard to stimulation of immune cell 
migration into the inflamed tissue, remains to be clarified in 
future studies.
Finally, there is the question of why a slight reduction 
of Z potential (around 10 mV) caused such a large effect on 
NP–cell interaction. This may be due to the formation of 
a protein corona around the surface of the NP. It has been 
shown for polystyrene NP that the properties of NP determine 
the protein corona, with possible implications for biological 
impacts.42 This is consistent with a more recent study, in 
which PVA-SPION with varying Z potentials were incubated 
with fetal bovine serum at fixed serum/particle ratios.43 The 
analysis of tightly bound proteins revealed that neutral and 
positively charged PVA-coated NP bound a wide range of 
serum proteins, with similar patterns, whereas the number 
of bound proteins decreased on the surface of negatively 
charged PVA-NP. Interestingly, the number of bound protein 
types reduced around 40% in positively (+13 mV), compared 
with highly positively (+34 mV), charged particles.43 Other 
investigators have also demonstrated that protein corona 
depends on charge, and even conclude that this may lead to 
unintended uptake by the body (eg, the brain) with potentially 
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In conclusion, we demonstrate that the surface characteristics 
of SPION strongly influence their biocompatibility. Our 
results prove that the newly formulated a-PVA-grafted-
SPION (+) are potentially suitable for use as a theragnostic 
agent, since they provoke fewer inflammatory effects, as a 
result of careful control and accurate definition of their sur-
face chemistry. These factors should always be considered 
in future investigations of this kind.
Further developments of nanomaterials will facilitate the 
diagnosis and therapy of chronic inflammatory autoimmune 
diseases. NP are taken up by different cell types and pro-
vide a basis for targeted cell-based therapy. The various uptake 
mechanisms of NP are affected by their properties, including 
the type of surface coating and the surface charge. We clearly 
demonstrated that a small variation in the surface charge influ-
ences the effects of NP on cells of the immune system, which 
may, at least in part, be caused by the composition of the protein 
corona. Therefore, it may be advantageous to analyze protein 
coronas and the correlation of their composition with cellular 
uptake mechanisms. This could be beneficial for applications 
which aim to achieve site-directed targeting leading to very 
early treatment and/or visualization of tissue inflammation. 
This would enable early therapeutic intervention prior to the 
onset of significant joint damage in rheumatoid arthritis.
Future studies should focus on the composition of the 
protein corona and cellular uptake of the PVA-grafted-
SPION (+) developed in the present work.
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Figure S1 Schematic representation (A) and photograph (B) of the magnetic reactor device used to obtain a-PVA-grafted-SPION. 
Notes: In step 1, the a-PVA-grafted-SPION were magnetically trapped for 1 hour and the excess of reactants washed out with DI water for 20 minutes. In step 2 the 
electromagnet was switched off and the washed a-PVA-grafted-SPION were released and stored. 
























Figure S2 Transmission electron microscope (TEM) images.
Notes: Naked SPION and SPION coated with adsorbed amino-PVA (a-PVA-SPION), PVA grafted with amino cross-linker (a-PVA-grafted-SPION [++]), and PVA grafted with 
amino cross-linker and with decrease of the global positive charge (a-PVA-grafted-SPION [+]). It was not possible to visualize the PVA coating of SPION by TEM; however, 
their shape and sizes are not clearly altered, 45,000× magnification.
Abbreviations: SPION, superparamagnetic iron oxide nanoparticles; PVA, polyvinyl alcohol.
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